Robust Dose Planning Objectives for Mesorectal Radiotherapy of Early Stage Rectal Cancer - A Multicentre Dose Planning Study

Overview

Journal Tech Innov Patient Support Radiat Oncol

Date 2020 Feb 26

PMID 32095545

Citations 11

Authors

Ane L Appelt

Ellen M Kerkhof

Lars Nyvang

Ernst C Harderwijk

Natalie L Abbott

Mark Teo

Femke P Peters

Camilla J S Kronborg

Karen-Lise G Spindler

David Sebag-Montefiore

Corrie A M Marijnen

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Organ preservation strategies are increasingly being explored for early rectal cancer. This requires revision of target volumes according to disease stage, as well as new guidelines for treatment planning. We conducted an international, multicentre dose planning study to develop robust planning objectives for modern radiotherapy of a novel mesorectal-only target volume, as implemented in the STAR-TReC trial (NCT02945566).

Materials And Methods: The published literature was used to establish relevant dose levels for organ at risk (OAR) plan optimisation. Ten representative patients with early rectal cancer were identified. Treatment scans had mesorectal target volumes as well as bowel cavity, bladder and femoral heads outlined, and were circulated amongst the three participating institutions. Each institution produced plans for short course (SCRT, 5 × 5 Gy) and long course (LCRT, 25 × 2 Gy) treatment, using volumetric modulated arc therapy on different dose planning systems. Optimisation objectives for OARs were established by determining dose metric objectives achievable for ≥90% of plans.

Results: Sixty plans, all fulfilling target coverage criteria, were produced. The planning results and literature review suggested optimisation objectives for SCRT:  < 180 cm,  < 110 cm,  < 85 cm for bowel cavity;  < 15% and  < 5% for bladder; and  < 11% for femoral heads. Corresponding objectives for LCRT:  < 180 cm,  < 130 cm,  < 90 cm for bowel cavity;  < 22% and  < 7% for bladder; and  < 15% for femoral heads. Constraints were validated across all three institutions.

Conclusion: We utilized a multicentre planning study approach to develop robust planning objectives for mesorectal radiotherapy for early rectal cancer.

Citing Articles

Dosimetric comparison of VMAT plans in preoperative short-course rectal radiotherapy.

Zhou Q, Wang Q, Li Y, Shen C, Sun X Sci Rep. 2024; 14(1):30862.

PMID: 39730522 PMC: 11680786. DOI: 10.1038/s41598-024-81310-4.

Dose tracking assessment for magnetic resonance guided adaptive radiotherapy of rectal cancers.

Xin X, Tang B, Wu F, Lang J, Li J, Wang X Radiat Oncol. 2024; 19(1):114.

PMID: 39218934 PMC: 11367860. DOI: 10.1186/s13014-024-02508-4.

Potential dosimetric error in the adaptive workflow of a 1.5 T MR-Linac from patient movement relative to immobilisation systems.

Liu M, Tang B, Orlandini L, Li J, Wang X, Peng Q Phys Eng Sci Med. 2024; 47(1):351-359.

PMID: 38227140 PMC: 10963571. DOI: 10.1007/s13246-023-01369-7.

Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer.

Bonilla C, Montenegro P, OConnor J, Hernando-Requejo O, Aranda E, Pinto Llerena J Cancers (Basel). 2023; 15(17).

PMID: 37686649 PMC: 10487247. DOI: 10.3390/cancers15174373.

Effectiveness of bladder filling control during online MR-guided adaptive radiotherapy for rectal cancer.

Feng X, Tang B, Yao X, Liu M, Liao X, Yuan K Radiat Oncol. 2023; 18(1):136.

PMID: 37592338 PMC: 10436664. DOI: 10.1186/s13014-023-02315-3.

References

Chi A, Nguyen N, Xu J, Ji M, Tang J, Jin J . Correlation of three different approaches of small bowel delineation and acute lower gastrointestinal toxicity in adjuvant pelvic intensity-modulated radiation therapy for endometrial cancer. Technol Cancer Res Treat. 2012; 11(4):353-9. DOI: 10.7785/tcrt.2012.500283. View

Han K, Cummings B, Lindsay P, Skliarenko J, Craig T, Le L . Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. Int J Radiat Oncol Biol Phys. 2014; 90(3):587-94. DOI: 10.1016/j.ijrobp.2014.06.061. View

Gunnlaugsson A, Kjellen E, Nilsson P, Bendahl P, Willner J, Johnsson A . Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer. Acta Oncol. 2007; 46(7):937-44. DOI: 10.1080/02841860701317873. View

Tho L, Glegg M, Paterson J, Yap C, MacLeod A, McCabe M . Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning. Int J Radiat Oncol Biol Phys. 2006; 66(2):505-13. DOI: 10.1016/j.ijrobp.2006.05.005. View

McDonald F, Waters R, Gulliford S, Hall E, James N, Huddart R . Defining bowel dose volume constraints for bladder radiotherapy treatment planning. Clin Oncol (R Coll Radiol). 2014; 27(1):22-9. DOI: 10.1016/j.clon.2014.09.016. View

Pares O, Santiago I, Greco C, Heald R . Total Mesorectal Irradiation: The "Next Step" in the Multidisciplinary Management of Rectal Adenocarcinoma?. Dis Colon Rectum. 2016; 59(12):1222-1226. DOI: 10.1097/DCR.0000000000000689. View

Olsen J, Moughan J, Myerson R, Abitbol A, Doncals D, Johnson D . Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529. Int J Radiat Oncol Biol Phys. 2017; 98(2):400-408. PMC: 5639877. DOI: 10.1016/j.ijrobp.2017.02.005. View

van de Schoot A, van den Wollenberg W, Carbaat C, de Ruiter P, Nowee M, Pos F . Evaluation of plan quality in radiotherapy planning with an MR-linac. Phys Imaging Radiat Oncol. 2021; 10:19-24. PMC: 7807609. DOI: 10.1016/j.phro.2019.04.004. View

Jorgensen J, Bondeven P, Iversen L, Laurberg S, Pedersen B . Pelvic insufficiency fractures frequently occur following preoperative chemo-radiotherapy for rectal cancer - a nationwide MRI study. Colorectal Dis. 2018; 20(10):873-880. DOI: 10.1111/codi.14224. View

10.

Sanguineti G, Endres E, Sormani M, Parker B . Dosimetric predictors of diarrhea during radiotherapy for prostate cancer. Strahlenther Onkol. 2009; 185(6):390-6. DOI: 10.1007/s00066-009-1953-4. View

11.

Rombouts A, Al-Najami I, Abbott N, Appelt A, Baatrup G, Bach S . Can we ave the rectum by watchful waiting or ransnal microsurgery following (chemo) adiotherapy versus otal mesorectal excision for early ctal ancer (STAR-TREC study)?: protocol for a multicentre, randomised feasibility study. BMJ Open. 2017; 7(12):e019474. PMC: 5770914. DOI: 10.1136/bmjopen-2017-019474. View

12.

Baglan K, Frazier R, Yan D, Huang R, Martinez A, Robertson J . The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2002; 52(1):176-83. DOI: 10.1016/s0360-3016(01)01820-x. View

13.

Sini C, Noris Chiorda B, Gabriele P, Sanguineti G, Morlino S, Badenchini F . Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: First quantification of bowel dose-volume effects. Radiother Oncol. 2017; 124(2):296-301. DOI: 10.1016/j.radonc.2017.07.005. View

14.

Isohashi F, Mabuchi S, Yoshioka Y, Seo Y, Suzuki O, Tamari K . Intensity-modulated radiation therapy versus three-dimensional conformal radiation therapy with concurrent nedaplatin-based chemotherapy after radical hysterectomy for uterine cervical cancer: comparison of outcomes, complications, and dose-volume.... Radiat Oncol. 2015; 10:180. PMC: 4554318. DOI: 10.1186/s13014-015-0486-5. View

15.

Yang T, Oh J, Son C, Apte A, Deasy J, Wu A . Predictors of acute gastrointestinal toxicity during pelvic chemoradiotherapy in patients with rectal cancer. Gastrointest Cancer Res. 2013; 6(5-6):129-36. PMC: 3849899. View

16.

van der Sande M, Hupkens B, Berbee M, van Kuijk S, Maas M, Melenhorst J . Impact of radiotherapy on anorectal function in patients with rectal cancer following a watch and wait programme. Radiother Oncol. 2019; 132:79-84. DOI: 10.1016/j.radonc.2018.11.017. View

17.

Fiorino C, Valdagni R, Rancati T, Sanguineti G . Dose-volume effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol. 2009; 93(2):153-67. DOI: 10.1016/j.radonc.2009.08.004. View

18.

Robertson J, Sohn M, Yan D . Predicting grade 3 acute diarrhea during radiation therapy for rectal cancer using a cutoff-dose logistic regression normal tissue complication probability model. Int J Radiat Oncol Biol Phys. 2009; 77(1):66-72. DOI: 10.1016/j.ijrobp.2009.04.048. View

19.

Isohashi F, Yoshioka Y, Mabuchi S, Konishi K, Koizumi M, Takahashi Y . Dose-volume histogram predictors of chronic gastrointestinal complications after radical hysterectomy and postoperative concurrent nedaplatin-based chemoradiation therapy for early-stage cervical cancer. Int J Radiat Oncol Biol Phys. 2012; 85(3):728-34. DOI: 10.1016/j.ijrobp.2012.05.021. View

20.

Feuvret L, Noel G, Mazeron J, Bey P . Conformity index: a review. Int J Radiat Oncol Biol Phys. 2006; 64(2):333-42. DOI: 10.1016/j.ijrobp.2005.09.028. View